Nearly 10,000 heart attack patients to test ancient pill for better recovery
NCT ID NCT07153744
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This large study will test whether adding Shexiang Baoxin Pill (Muskardia) to standard treatment helps people who have had a heart attack. About 9,588 participants will receive either standard care alone or standard care plus the pill for 12 months. The goal is to see if the pill lowers the chance of further heart problems, stroke, or death.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Shexiang Baoxin Pill (Muskardia)
What this could lead to
If it works, this could provide a new add-on treatment to reduce the risk of further heart problems and improve recovery after a heart attack.
What could go wrong
This is a phase 4 real-world study, so it builds on existing knowledge rather than testing a brand-new approach. The pill may not significantly lower complication rates beyond standard care, and individual results may vary.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERCUTANEOUS CORONARY INTERVENTION (PCI) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital, Fudan University
Shanghai, 200032, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact